Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation

// Roberta Vene 1,2 , Francesca Tosetti 2 , Simona Minghelli 1,2 , Alessandro Poggi 2 , Nicoletta Ferrari 2 and Roberto Benelli 1 1 Immunology Lab, IRCCS AOU San Martino - IST, Genoa, Italy 2 Molecular Oncology and Angiogenesis Lab, IRCCS AOU San Martino - IST, Genoa, Italy Correspondence to: Roberto Benelli, email: // Keywords : EGFR, celecoxib, colon, fibroblast Received : October 01, 2014 Accepted : March 11, 2015 Published : March 29, 2015 Abstract We previously demonstrated that non-toxic doses of Celecoxib induced the immediate phosphorylation of Erk1-2 in colon tumor associated fibroblasts (TAFs), increasing their responsiveness to epidermal growth factor (EGF). We have now identified two concomitant mechanisms explaining the EGF-Celecoxib cooperation. We found that a 24-48h Celecoxib priming increased EGF receptor (EGFR) mRNA and protein levels in colon TAFs, promoting EGF binding and internalization. Celecoxib-primed TAFs showed a reduced EGFR degradation after EGF challenge. This delay corresponded to a deferred dissociation of EEA1 from EGFR positive endosomes and the accumulation of Rab7, pro Cathepsin-D and SQSTM1/p62, suggesting a shared bottleneck in the pathways of late-endosomes/autophagosomes maturation. Celecoxib modulated the levels of target proteins similarly to the inhibitors of endosome/lysosome acidification Bafilomycin-A1 and NH 4 Cl. Cytoplasmic vesicles fractionation showed a reduced maturation of Cathepsin-D in late endosomes and an increased content of EGFR and Rab7 in lysosomes of Celecoxib-treated TAFs. Our data indicate a double mechanism mediating the increased response to EGF of colon TAFs treated with Celecoxib. While EGFR overexpression could be targeted using anti EGFR drugs, the effects on endosome trafficking and protein turnover represents a more elusive target and should be taken into account for any long-term therapy with Celecoxib.